Core Points - Kangwei Century (688426.SH) closed at 26.49 yuan, with a decline of 4.71%, currently in a state of breaking issue [1] - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on October 25, 2022, with an initial offering price of 48.98 yuan per share [1] - The total number of shares publicly issued was 23,290,278, accounting for 25% of the total share capital after issuance [1] - The total funds raised amounted to 1,140.76 million yuan, with a net amount of 1,054.30 million yuan after deducting issuance costs, exceeding the original plan by 68.63 million yuan [1] - The funds are intended for projects including the industrialization of medical devices and biological testing reagents, marketing network construction, molecular detection product R&D, and working capital supplementation [1] Financial Details - The issuance costs totaled 86.45 million yuan, with CITIC Securities receiving underwriting fees of 64.49 million yuan [2] - CITIC Securities Investment Co., Ltd., a related subsidiary involved in the underwriting, was allocated 931,611 shares, representing 4.00% of the total shares issued [2] - On June 6, 2023, the company announced a dividend plan of 5.2 yuan (pre-tax) per 10 shares, with a bonus issue of 2 shares [2]

Core Points - Huaru Technology's stock price fell by 3.39% to 22.81 yuan as of the market close [1] - The company went public on June 23, 2022, on the Shenzhen Stock Exchange's ChiNext board, with an initial offering price of 52.03 yuan per share [1] - Currently, the stock is in a state of decline, having broken its initial offering price [1] Fundraising and Financials - Huaru Technology raised a total of 137,203.11 million yuan through its initial public offering, with a net amount of 127,524.55 million yuan [1] - The net fundraising amount exceeded the original plan by 47,524.55 million yuan [1] - The company initially aimed to raise 80,000 million yuan for various projects, including a new generation combat system and a multidisciplinary collaborative design and simulation platform [1] Issuance Costs - The total issuance costs for the initial public offering amounted to 9,678.56 million yuan, with underwriting fees accounting for 8,232.19 million yuan [1] Stock Adjustment - On May 25, 2023, Huaru Technology announced a stock split of 10 shares for every 5 shares held, with a tax-free dividend of 0 yuan [1] - The ex-rights and ex-dividend date was set for June 1, 2023, with the record date on May 31, 2023 [1]

每经头条（nbdtoutiao）——灌水21万亿，高市早苗1.7万亿强化国防！日本负债率已远超债务危机时的 希腊，对美巨额投资致大规模资本外流，"卖出日元成国际趋势" （记者 曾健辉） 每经AI快讯，当升科技（SZ 300073，收盘价：58.74元）发布公告称，2025年11月26日10:00-11:30，当 升科技接受中信证券等投资者调研，公司副总经理、磷系产品线总经理、当升蜀道董事长陈新参与接 待，并回答了投资者提出的问题。 2025年1至6月份，当升科技的营业收入构成为：非金属矿物制品占比98.35%，专用设备制造业占比 1.65%。 截至发稿，当升科技市值为320亿元。 ...

Core Viewpoint - Shanghai Bao Pharmaceuticals Co., Ltd. (referred to as "Bao Pharmaceuticals") is preparing for an IPO on the Hong Kong Stock Exchange, having submitted its prospectus after hearing on November 26, 2025, following two previous submissions in January and August 2025 [1][5]. Business Overview - Bao Pharmaceuticals, established in 2019, is a clinical-stage biotechnology company focused on developing and providing recombinant biopharmaceuticals in China using synthetic biology technology. The company targets complex diseases with limited treatment options [5]. - The company strategically focuses on four key areas: (i) large-volume subcutaneous delivery, (ii) antibody-mediated autoimmune diseases, (iii) assisted reproduction, and (iv) recombinant biopharmaceuticals [5]. Product Pipeline - Bao Pharmaceuticals has a pipeline of 12 self-developed products, including three core products: KJ017, KJ103, and SJ02 (Shengnuo). Additionally, there are four other clinical-stage candidates and five preclinical assets [5]. - The core product SJ02 received NDA approval from the National Medical Products Administration (NMPA) in August 2025. KJ017 and KJ103 are in late clinical or NDA registration stages in China [6]. - SJ02 is a long-acting recombinant human follicle-stimulating hormone-CTP fusion protein designed for controlled ovarian stimulation in conjunction with GnRH antagonists. KJ017 is the first recombinant hyaluronidase in China aimed at rapid, large-volume subcutaneous delivery. KJ103 is an innovative recombinant IgG-degrading enzyme for treating various immune diseases [6]. Clinical Trials - Bao Pharmaceuticals is actively advancing multiple pipeline products, particularly innovative recombinant biopharmaceuticals as transformative alternatives to traditional biochemical extraction drugs, including KJ101 and BJ044 [6]. - The company has developed recombinant human chorionic gonadotropin (hCG) SJ04 for assisted reproduction, which received IND approval in May 2024 and began Phase I clinical trials in August 2024, completing the trial in September 2025 [7]. Financial Performance - The company's revenue for the years 2023, 2024, and the first half of 2025 was RMB 6.93 million, RMB 6.16 million, and RMB 4.199 million, respectively. Corresponding R&D expenditures were RMB 133 million, RMB 251 million, and RMB 111 million, with net losses of RMB 160 million, RMB 364 million, and RMB 183 million [16][17]. Shareholder Structure - The pre-IPO shareholder structure shows Dr. Liu Yanjun holding 21.21%, Ms. Wang Zheng 7.81%, and Mr. Tan Jingwei 5.21%. Other significant shareholders include Shengde Pharmaceutical and various investment funds [9][10].

Core Viewpoint - Tianyu Semiconductor, a Chinese silicon carbide epitaxial wafer manufacturer, is launching an IPO to raise approximately HKD 1.744 billion, with shares priced at HKD 58 each [1] Fundraising and Allocation - The company is offering 30.07 million H-shares, with 10% allocated for public offering in Hong Kong and 90% for international placement [1] - The net proceeds from the IPO will be allocated as follows: - Approximately 62.5% for expanding overall production capacity over the next five years to enhance market share and product competitiveness [1] - About 15.1% for improving independent research and innovation capabilities to enhance product quality and shorten new product development cycles [1] - Around 10.8% for strategic investments or acquisitions to expand the customer base, enrich the product portfolio, and supplement technology [1] - Approximately 2.1% for expanding global sales and marketing networks [1] - About 9.5% for working capital and general corporate purposes [1] Listing Information - The stock is expected to be listed for trading on December 5 [1] - The entry fee for one lot of 50 shares is HKD 2,929.24 [1]

Core Viewpoint - CITIC Securities reports that Kelun-Biotech's core product, Sacituzumab Govitecan, has received MNC recognition and global development capabilities, enhancing its potential in combination with Merck's Keytruda for ADC+IO applications. The accelerated global development process and imminent domestic commercialization lead to a target price of HKD 592, maintaining a "Buy" rating [1] Group 1: Product Development - Kelun-Biotech announced that its core product TROP2-ADC, Sacituzumab Govitecan, in combination with Pembrolizumab, achieved the primary endpoint in a Phase III clinical trial for PD-L1 positive non-small cell lung cancer (NSCLC) [1] - This trial marks the first positive Phase III study for ADC combined with immune checkpoint inhibitors in the first-line NSCLC setting globally, confirming the treatment potential of Sacituzumab Govitecan [1] Group 2: Pipeline and Market Potential - The positive trial results further validate the combined treatment potential of Sacituzumab Govitecan, alongside its three approved indications and multiple ongoing clinical trials, indicating a continuous realization of pipeline value [1]

Core Viewpoint - CITIC Securities reports that Kelun-Biotech (06990) has received MNC recognition for its core product, sac-TMT/SKB264/MK-2870, and is accelerating its global development capabilities, leading to a target price of HKD 592 and a "Buy" rating [1] Group 1: Product Development - The core product, TROP2ADC sac-TMT/SKB264/MK-2870, has achieved the primary endpoint in a Phase III clinical study for first-line treatment of PD-L1 positive non-small cell lung cancer (NSCLC) in combination with pembrolizumab [1] - This study marks the first positive Phase III result for an ADC combined with immune checkpoint inhibitors in the first-line NSCLC setting globally, confirming the treatment potential of sac-TMT/SKB264/MK-2870 [1] Group 2: Market Potential - The product has already received approval for three indications and has multiple ongoing clinical trials, indicating a continuous realization of pipeline value [1] - The combination of sac-TMT/SKB264/MK-2870 with Merck's Keytruda (pembrolizumab) further explores the potential of ADC + IO combination therapies [1]

Core Viewpoint - CITIC Securities reports a target price of $206 per ADR and HKD 201 per share for Alibaba, maintaining a "Buy" rating based on a segmented valuation approach for FY2027 [1] Segment Summaries - **E-commerce Business Valuation**: Alibaba's e-commerce business is assigned a valuation of 10x P/EBITA for FY2027, with instant retail receiving a valuation of 0 [1] - **Cloud Computing Valuation**: The cloud computing segment is valued at 5x PS, indicating strong performance that exceeds market expectations [1] - **International E-commerce Valuation**: The international e-commerce business is assigned a valuation of 1x PS [1] - **Financial Performance**: The company’s FY2026 Q2 CMR revenue growth remains at 10%, with the Taotian Group achieving single-digit growth in EBITA after excluding flash purchase losses [1] - **Flash Purchase Business**: The flash purchase segment is transitioning from scale expansion to efficiency optimization, with expected losses aligning with forecasts [1] - **AI Revenue Growth**: In FY2026 Q2, capital expenditure reached 31.5 billion, with cloud revenue growing by 34%, and AI revenue showing a three-digit year-on-year increase, accounting for over 20% of total revenue [1] - **Future Outlook for Cloud Business**: Alibaba Cloud is expected to continue its "one cloud, multiple chips" strategy to meet strong AI customer demand, with revenue growth in the cloud business anticipated to accelerate [1]

Core Viewpoint - CITIC Securities has issued a report valuing Alibaba (09988, BABA.US) with a target price of $206 per ADR and HKD 201 per share for its FY2027, maintaining a "Buy" rating based on a segmented valuation approach [1] Segment Summaries - **E-commerce Business Valuation**: Alibaba's e-commerce business is assigned a 10x P/EBITA valuation for FY2027, while instant retail is valued at 0, and international e-commerce at 1x PS [1] - **Cloud Computing Performance**: The cloud computing segment is valued at 5x PS, with revenue growth exceeding market expectations, indicating a strong performance [1] - **Financial Metrics**: The report suggests a FY2027 Non-GAAP PE of 24x for the group, reflecting positive financial outlooks [1] - **Consumer Market Revenue (CMR)**: For FY2026 Q2, CMR revenue growth remains at 10%, with the Taotian Group achieving single-digit growth in EBITA after excluding flash purchase losses [1] - **Flash Purchase Business**: The flash purchase segment is transitioning from scale expansion to efficiency optimization, with expected losses aligning with forecasts, while benefiting from synergies with e-commerce [1] - **AI Revenue Growth**: In FY2026 Q2, capital expenditure reached 31.5 billion, with cloud revenue growing by 34%, surpassing market expectations, and AI revenue showing triple-digit year-on-year growth, accounting for over 20% of total revenue [1] - **Future Cloud Strategy**: Alibaba Cloud will continue to implement a "one cloud, multiple chips" strategy to meet strong AI customer demand, with expectations of accelerated revenue growth in the cloud business [1]

Core Insights - Baoyi Pharmaceutical has passed the main board listing hearing on the Hong Kong Stock Exchange, with CITIC Securities and Guotai Junan acting as joint sponsors [1] - The company's core product, SJ02 (Shengnuowa®), is a long-acting recombinant human follicle-stimulating hormone carboxy-terminal peptide fusion protein for assisted reproduction, which received NDA approval from the National Medical Products Administration in August 2025 [1] - Two other core products, KJ103 (an innovative recombinant immunoglobulin G (IgG) degrading enzyme in Phase III development) and KJ017 (a recombinant hyaluronidase in NDA stage), are in late-stage trials or NDA registration in China [1] - The company's strategy focuses on four key areas: large-volume subcutaneous delivery, antibody-mediated autoimmune diseases, assisted reproduction, and recombinant biopharmaceuticals [1] - According to Frost & Sullivan, the total clinical addressable market size for the company's four strategic therapeutic areas in China is expected to reach approximately RMB 50 billion by 2033 [1]